Patent details

EP3134119 Title: CANCER TREATMENT

Basic Information

Publication number:
EP3134119
PCT Application Number:
IB2015052796
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP157292228
PCT Publication Number:
WO2015162532
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
CANCER TREATMENT
French Title of Invention:
TRAITEMENT ANTICANCÉREUX
German Title of Invention:
KREBSBEHANDLUNG
SPC Number:

Dates

Filing date:
16/04/2015
Grant date:
22/08/2018
EP Publication Date:
01/03/2017
PCT Publication Date:
29/10/2015
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
22/08/2018
EP B1 Publication Date:
22/08/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
16/04/2022
Expiration date:
16/04/2035
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
15/08/2018
 
 

Name:
Pfizer Inc.
Address:
235 East 42nd Street, New York, NY 10017, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
03/10/2018
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
WILLIAMS, James Andrew
Address:
United States (US)

2

Name:
MARTINI, Jean-Francois Andre
Address:
United States (US)

3

Name:
TARAZI, Jamal Christo
Address:
United States (US)

Priority

Priority Number:
201461983951 P
Priority Date:
24/04/2014
Priority Country:
United States (US)

Classification

IPC classification:
A61K 39/395; G01N 33/574;

Publication

European Patent Bulletin

Issue number:
201834
Publication date:
22/08/2018
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
22/03/2021
Last Annual Fee Paid Number:
7
Last Annual Fee Paid Amount:
82 Euro
Payer:
MASTER DATA CENTER INC (ex Clarivate Analytics)
Filing date Document type Number of pages
03/10/2018 Power Of Attorney 1
15/10/2018 Outgoing Correspondence 1